Investigational drug · Phase 3
pulocimab
Also called: AK109
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Gastric and Gastroesophageal Junction Adenocarcinoma, Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma, Advanced Solid Tumor.
Phase 3Last checked: Nov 19, 2026Latest source record: Nov 19, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
1
Any phase or sponsor naming "pulocimab"
First trial start
2021
Aug 23, 2021
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "pulocimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Gastric and Gastroesophageal Junction Adenocarcinoma
- Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma
- Advanced Solid Tumor
Approved drugs for the same conditions: Stomach and esophageal cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "pulocimab" as an intervention, largest first.
- A Study of AK104/Placebo Plus AK109/Placebo And Paclitaxel in Gastric or Gastroesophageal Junction AdenocarcinomaPivotal-lookingRecruiting
AkesoIndustry
NCT06341335 · 506 participants (planned) · Start Jun 19, 2024 · Primary completion Nov 2026
Drug: cadonilimab; pulocimab and 2 more · For: Gastric and Gastroesophageal Junction Adenocarcinoma
Sites: Beijing, China
Newest research
PubMed records naming it or its code names, newest first.
- First-in-human, phase I study of AK109, an anti-VEGFR2 antibody in patients with advanced or metastatic solid tumors.
Zheng Y, Zhong H, Zhao F, et al. · ESMO Open 2023
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.